Diagnosing PPF and the Importance of Early Detection

Opinion
Video

Anna-Maria Hoffmann-Vold, M.D., Ph.D., discusses how progressive pulmonary fibrosis is diagnosed in clinical practice, the barriers hindering early diagnosis, strategies to overcome these challenges and the critical role of early detection and intervention in improving patient outcomes and reducing long-term healthcare costs.

Video content above is prompted by the following:

  • How is progressive pulmonary fibrosis (PPF) diagnosed in clinical practice?
  • What barriers hinder early diagnosis, and what strategies can be implemented to address these barriers?
  • What is the role of early diagnosis and intervention in improving patient outcomes in PPF?
  • How can early detection and intervention reduce long-term healthcare costs for patients?

Newsletter

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!
Recent Videos
1 expert in this video
1 expert in this video
1 expert in this video
1 expert in this video
2 experts are featured in this series.
1 expert is featured in this series.
1 expert in this video
1 expert in this video
Related Content
Enhancing Patient Care in Progressive Pulmonary Fibrosis: Strategies for Addressing Unmet Needs and Optimizing Treatment Approaches

Enhancing Patient Care in Progressive Pulmonary Fibrosis: Strategies for Addressing Unmet Needs and Optimizing Treatment Approaches

Peter Wehrwein, Managing Editor
August 4th 2025
Article

Progressive pulmonary fibrosis is not a diagnosis so much as a disease behavior and a clinical phenotype, says Anna-Maria Hoffmann-Vold, M.D., Ph.D., of Oslo University Hospital and the expert featured on this MHE K-Cast.

Read More

Value-Based Decision-Making in Metastatic Breast Cancer

Value-Based Decision-Making in Metastatic Breast Cancer

Ian E. Krop, MD, PhD;Debra Patt, MD, PhD, MBA
August 4th 2025
Article

In this Managed Healthcare Executive® KCast, Ian Krop, M.D., Ph.D., oncologist and associate professor of medicine at Dana-Farber Cancer Institute in Boston, and Debra Patt, M.D., Ph.D., MBA, executive vice president at Texas Oncology in Austin, provide key insights into the value-based care model for patients with HER2-positive metastatic breast cancer (mBC). This article summarizes the highlights of the discussion.

Read More

© 2025 MJH Life Sciences

All rights reserved.